by Peter Ciszewski | Oct 25, 2022
The U.S. Food and Drug Administration (FDA) has given accelerated approval to teclistamab-cqyv (Tecvayli) to treat adults with with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor,...
by Peter Ciszewski | Oct 22, 2022
Ronald Martell, President, and CEO of Jasper Therapeutics, discusses the positive data from the ongoing phase 1/2 study testing JSP191 as a conditioning agent in the treatment of Fanconi anemia. These data were presented at the annual conference of the Inborn...
by Peter Ciszewski | Oct 19, 2022
Ricardo Dolmetsch, PhD, President of Research and Development at uniQure, discusses what he thinks physicians should know about gene therapy. Huntington disease is an inherited, neurodegenerative disorder that usually begins to be symptomatic starting at around...
by Peter Ciszewski | Oct 18, 2022
Evan S. Dellon, MD, MPH, Gastroenterologist, and Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina Chapel Hill, explains two things that physicians should know about eosinophilic esophagitis (EoE). EoE is a chronic,...
by Peter Ciszewski | Oct 17, 2022
Pam Vig, PhD, Head of Research & Development at Mirum Pharmaceuticals, discusses how the approval of maralixibat has changed the management of Alagille syndrome. Alagille syndrome is a genetic disorder that can affect the liver, heart, skeleton, eyes, and...
